Zai Lab Ltd (ZLAB) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 38 days, typically, give or take 9 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026before open 36 8-K
Q2 FY2026Thu, Aug 6, 2026before open 37 8-K
Q1 FY2026Thu, May 7, 2026before open 37 8-K
Q4 FY2025Thu, Feb 26, 2026before open 57 8-K
Q3 FY2025Thu, Nov 6, 2025before open 37 8-K
Q2 FY2025Thu, Aug 7, 2025before open 38 8-K
Q1 FY2025Thu, May 8, 2025before open 38 8-K
Q4 FY2024Thu, Feb 27, 2025before open 58 8-K

What they guided beta

Q3 FY2026 "Document Exhibit 99.1 Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates Zai Lab anticipates major catalysts in 2027 across multiple global programs with transformative potential: – Zoci 1.6 mg/kg plus atezolizumab showed compelling 1L SCLC data at ESMO: 81.8% confirmed ORR, an estimated 81.9% six-month PFS rate and 9.1% Grade ≥3 zoci-related AEs; advancing toward a global Phase 3 study in 1L SCLC – Registrational global Phase 3 DLLEVATE study evaluating zoci in 2L+ SCLC is ongoing, with a potential interim analysis in the second half of 2027, followed by a sub" exhibit
Q3 FY2026 "Together with our commercially profitable China business, which we expect to return to growth in 2027, these advancements position Zai Lab to create substantial value for patients and shareholders.”" exhibit
Q3 FY2026 "We will present first-in-human data at ACAAI in November and initial patient data in the first half of 2027, and we expect two additional oncology and immunology programs to enter the clinic in 2027.” 1 Third Quarter 2026 Financial Results" exhibit
Q3 FY2026 "Based on feedback from the U.S. Food and Drug Administration (FDA), Zai Lab will pursue a potential accelerated approval pathway based on this single-arm expansion study with topline data expected in the first half of 2027." exhibit
Q3 FY2026 "In October 2026, Zai Lab announced that initial first-in-human data from the single ascending dose (SAD) portion of the global Phase 1/1b study in healthy volunteers is expected to be shared for the first time at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, taking place November 12–16, 2026, in Phoenix, AZ." exhibit
Q2 FY2026 "Document Exhibit 99.1 Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates – The Company advanced multiple global oncology and immunology programs toward key clinical and regulatory milestones, with significant pipeline catalysts expected in the second half of 2026 – Global Phase 1 data for zocilurtatug pelitecan (zoci) in combination with a PD-L1 inhibitor in first-line SCLC to be presented at ESMO 2026; planned initiation of a registrational Phase 3 study later this year – Registrational Phase 3 DLLEVATE study evaluating zoci in second-line plus SCLC remains o" exhibit
Q2 FY2026 "In the second half of the year, we expect to further stabilize product sales while laying the foundation for a return to meaningful growth in 2027." exhibit
Q2 FY2026 "Zocilurtatug Pelitecan (zoci, DLL3-Targeting ADC) (formerly ZL-1310): – In July 2026, Zai Lab received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for zoci for the treatment of neuroendocrine carcinomas (NECs). – In June 2026, Zai Lab received ODD from the European Medicines Agency (EMA) for zoci for the treatment of patients with pulmonary NECs. – In May 2026, Zai Lab received Fast Track Designation from the FDA for zoci for the treatment of patients with epNECs." exhibit
Q2 FY2026 "ZL-1503 (IL-13/IL-31Rα): Completed enrollment in the single ascending dose (SAD) portion of the Phase 1/1b study of ZL-1503 in healthy volunteers, with initial PK, PD, safety and immunogenicity data expected in the second half of 2026." exhibit
Q2 FY2026 "Zai Lab participated in the global Phase 3 RAINIER study in Greater China. 3 Anticipated Major Milestones in 2026 and the First Half of 2027 Global Pipeline Expected Clinical Developments and Data Readouts Zocilurtatug Pelitecan (zoci, DLL3-Targeting ADC; formerly ZL-1310)" exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/ZLAB
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/ZLAB

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

ZLAB earnings date badge

HTML

<a href="https://veritasdata.dev/company/ZLAB/"><img src="https://veritasdata.dev/embed/ZLAB.svg" alt="ZLAB earnings date" width="240" height="56"></a>

Markdown

[![ZLAB earnings date](https://veritasdata.dev/embed/ZLAB.svg)](https://veritasdata.dev/company/ZLAB/)

Script

<script async src="https://veritasdata.dev/embed/ZLAB.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/ZLAB"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.